share_log

AstraZeneca | 6-K: Ultomiris Approved in the Us for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

SEC announcement ·  Mar 25 07:33
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more